On May 28, 2021, the U.S. Food and Drug Administration approved the Guardant360® CDx test for tumor mutation profiling or comprehensive genomic profiling to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who harbor the KRAS G12C mutation and may benefit from Lumakras™ (sotorasib), an FDA-approved KRASG12C inhibitor developed and manufactured by Amgen.
Read the Guardant Health announcement.
Posted 6/1/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
